Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Assunto principal
Intervalo de ano de publicação
1.
J Neurosci ; 43(26): 4941-4954, 2023 06 28.
Artigo em Inglês | MEDLINE | ID: mdl-37253603

RESUMO

Synaptic loss is intrinsically linked to Alzheimer's disease (AD) neuropathology and symptoms, but its direct impact on clinical symptoms remains elusive. The postsynaptic protein Shank3 (SH3 and multiple ankyrin repeat domains) is of particular interest, as the loss of a single allele of the SHANK3 gene is sufficient to cause profound cognitive symptoms in children. We thus sought to determine whether a SHANK3 deficiency could contribute to the emergence or worsening of AD symptoms and neuropathology. We first found a 30%-50% postmortem loss of SHANK3a associated with cognitive decline in the parietal cortex of individuals with AD. To further probe the role of SHANK3 in AD, we crossed male and female 3xTg-AD mice modelling Aß and tau pathologies with Shank3a-deficient mice (Shank3Δex4-9). We observed synergistic deleterious effects of Shank3a deficiency and AD neuropathology on object recognition memory at 9, 12, and 18 months of age and on anxious behavior at 9 and 12 months of age in hemizygous Shank3Δex4-9-3xTg-AD mice. In addition to the expected 50% loss of Shank3a, levels of other synaptic proteins, such as PSD-95, drebrin, and homer1, remained unchanged in the parietotemporal cortex of hemizygous Shank3Δex4-9 animals. However, Shank3a deficiency increased the levels of soluble Aß42 and human tau at 18 months of age compared with 3xTg-AD mice with normal Shank3 expression. The results of this study in human brain samples and in transgenic mice are consistent with the hypothesis that Shank3 deficiency makes a key contribution to cognitive impairment in AD.SIGNIFICANCE STATEMENT Although the loss of several synaptic proteins has been described in Alzheimer's disease (AD), it remains unclear whether their reduction contributes to clinical symptoms. The results of this study in human samples show lower levels of SHANK3a in AD brain, correlating with cognitive decline. Data gathered in a novel transgenic mouse suggest that Shank3a deficiency synergizes with AD neuropathology to induce cognitive impairment, consistent with a causal role in AD. Therefore, treatment aiming at preserving Shank3 in the aging brain may be beneficial to prevent AD.


Assuntos
Doença de Alzheimer , Animais , Feminino , Humanos , Masculino , Camundongos , Doença de Alzheimer/metabolismo , Peptídeos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Cognição , Modelos Animais de Doenças , Camundongos Transgênicos , Proteínas dos Microfilamentos , Proteínas do Tecido Nervoso , Proteínas tau/genética , Proteínas tau/metabolismo
2.
Photoacoustics ; 28: 100401, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36105377

RESUMO

We report on a gas sensor based on quartz-enhanced photoacoustic spectroscopy (QEPAS) able to detect multiple gas species for environmental monitoring applications, by exploiting a Vernier effect-based quantum cascade laser as the excitation source. The device emission spectrum consists of ten separated emission clusters covering the range from 2100 up to 2250 cm-1. Four clusters were selected to detect the absorption features of carbon monoxide (CO), nitrous oxide (N2O), carbon dioxide (CO2), and water vapor (H2O), respectively. The sensor was calibrated with certified concentrations of CO, N2O and CO2 in a wet nitrogen matrix. The H2O absorption feature was used to monitor the water vapor within the gas line during the calibration. Minimum detection limits of 6 ppb, 7 ppb, and 70 ppm were achieved for CO, N2O and CO2, respectively, at 100 ms of integration time. As proof of concept, the QEPAS sensor was tested by continuously sampling indoor laboratory air and monitoring the analytes concentrations.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...